Ipamorelin mechanism, half-life, and the published corpus — without the bro-science. A founder-operator reading of the selective ghrelin-receptor agonist literature.
Ipamorelin shows up in almost every founder-operator GH-axis stack on the forums, almost always paired with CJC-1295. It is the quieter half of the pair — the one with the cleaner receptor selectivity profile and the smaller side-effect footprint in the original pharmacology work. That selectivity is the entire reason it earned its place.
This page is the working reference. Mechanism, half-life, the corpus, the gaps. No dosing. No protocols.
Ipamorelin is a synthetic pentapeptide. Five amino acids, fully unnatural sequence, designed in the late 1990s as a selective growth hormone secretagogue. It belongs to the class called GHS — growth hormone secretagogues — and acts at the ghrelin receptor, formally GHSR-1a.
The design intent is the important part. The earlier ghrelin-receptor agonists — GHRP-2 and GHRP-6 — drove GH release effectively but also produced meaningful increases in cortisol and prolactin, two hormones the founder cohort generally does not want elevated. Ipamorelin was engineered to retain the GH-releasing activity while minimizing those off-target effects. In the original pharmacology, it did. That selectivity is why it survived into the contemporary research-peptide market while the older GHRPs largely did not.
It is not a GHRH analog. It does not bind the GHRH receptor. This is the structural reason it pairs with CJC-1295 (and with Sermorelin, and with Tesamorelin) — two different receptors, two different signals, additive GH release.
Ipamorelin binds GHSR-1a — the ghrelin receptor — on pituitary somatotrophs and on hypothalamic neurons. The endogenous ligand for this receptor is ghrelin, the gut-derived peptide most popularly known for appetite signaling. Receptor activation drives GH release through a Gq-mediated calcium signaling pathway, distinct from the cAMP pathway that GHRH triggers at its own receptor.
The two pathways converge on the same downstream output — GH release into circulation — through different intracellular signals. This is the mechanistic basis for the additivity that paired GHRH-analog plus ghrelin-receptor-agonist protocols are designed around.
The foundational pharmacology papers are Raun et al., 1998 in the European Journal of Endocrinology, which characterized the original peptide and its selectivity profile, and subsequent work by Hansen and colleagues that extended the receptor-binding and in vivo GH-release picture. The Raun paper is the one most people cite when they cite anything; it established the GH-selective profile that distinguished Ipamorelin from earlier GHRPs.
Two mechanism notes worth being explicit about. First: the appetite signaling that ghrelin produces at this receptor is real, and Ipamorelin binds the same receptor. Whether and how much appetite stimulation occurs at GH-releasing exposures in humans is part of what the community-report section below describes — and part of what the literature does not cleanly answer. Second: like CJC-1295, Ipamorelin signals upstream of the pituitary. It does not provide GH directly. If the somatotroph population is depleted or non-responsive, the compound has nothing to act on.
Ipamorelin has a reported plasma half-life of approximately 2 hours in human pharmacokinetic work. This is meaningfully longer than free GHRH, meaningfully shorter than CJC-1295 with DAC, and roughly in the range of CJC-1295 without DAC at the upper end.
The 2-hour half-life is what makes the compound useful for short, pulse-style protocols and what makes it functionally pairable with the without-DAC GHRH analogs. Both compounds clear the system in a window measured in hours rather than days, which approximates the natural pulsatile GH secretion pattern more closely than a multi-day depot does.
Route in published pharmacology work is subcutaneous injection. Intravenous administration appears in the early pharmacokinetic and challenge-test work but is not how the compound is used in research markets. Intranasal and oral preparations exist in community discussion. Published support for those routes — particularly for systemic GH release rather than local exposure — is thin.
The Ipamorelin published corpus sits at Tier 3 in our framework. Mechanism and pharmacokinetics are well-characterized in the original work. Outcome trials in healthy adults at the doses the founder cohort uses are essentially absent.
What the published work establishes:
What the published work does not establish:
The Raun paper and the immediate follow-on work are the corpus. Anything past that, in humans, on the endpoints the founder cohort cares about, is inferred from mechanism and from forum N=1.
Forum and N=1 reports across the founder-operator cohort are dense and reasonably consistent on Ipamorelin.
Sleep depth changes are the most reliably reported subjective effect, particularly when the compound is administered at night. Users describe deeper sleep onset and a shift toward more slow-wave sleep. The pattern overlaps with what CJC-paired protocols produce, which makes attribution to either compound alone hard from N=1 alone.
Hunger reports vary. Some users report a transient hunger spike consistent with ghrelin-receptor activation; others report nothing meaningful. Reports tend to describe the hunger effect as smaller than what GHRP-2 or GHRP-6 produced in the older community discussions.
Connective tissue and skin reports are softer than the GH-axis tier-1 compounds (Sermorelin and Tesamorelin) but appear in the multi-week window with consistent administration.
PIP reports are generally low. Reconstitution and storage practice variability is the more common source of complaint than the compound itself.
The shape of the unknown matches CJC-1295's, with one addition.
We do not have a randomized outcome trial of Ipamorelin in healthy adults at the exposures the cohort uses. We do not have long-term safety data. We do not have comparative effectiveness data against MK-677 — the orally bioavailable secretagogue — which is the most relevant within-class comparison.
The addition: we do not have a clean human characterization of how chronic ghrelin-receptor activation by a synthetic agonist interacts with appetite, body weight set point, and metabolic signaling over months. The receptor does more than release GH. The published Ipamorelin corpus is short-window pharmacology; the cohort runs the compound for far longer.
Issue 1 covers the GH-axis primer — both receptors, both compound classes, the case for and against pulsatile versus depot strategies. Ipamorelin is the ghrelin-receptor representative in that issue.
For readers in the GLP-1 cohort thinking about lean mass preservation under caloric deficit, the GHRH-analog side of the GH axis (Sermorelin, Tesamorelin) is closer to the published evidence base on lean mass than the ghrelin-receptor side is. Ipamorelin is more often the quiet pairing peptide in those stacks than the lead actor.
The Peptide Stack Map is the lead magnet on this page. Fourteen compounds, mechanism through literature, one page each.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
FTC disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full disclosure on the About page.
Subscribe to The Compound — the Sunday briefing on peptides for founder-operators.
[Subscribe — get the Peptide Stack Map]
14 compounds, half-lives, and the literature — one PDF.
Download the PDF →